Genmab — November 2019
-
there is this poster 1898 A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: https://ash.confex.com/ash/2019/webprogram/Paper129103.html on this trial https://clinicaltrials.gov/ct2/show/NCT03236428?term=daratumumab+smoldering&rank=1
-
God humor Solsen og nohope.
-
https://www.fda.gov/medical-devices/device-advice-investigational-device-exemption-ide/ide-application Ligner noget med målemetoden -
måske. -
-
Nye internationale tweets i Chat nyheder. Bla. denne The Economist @TheEconomist
Can money buy happiness? https://econ.st/36PrC2C
-
Fra Økonomisk Ugebrev: "Stadig potentiale i Genmab trods kursstigninger"
Fra 3. og sidste del i Genmab-føljetonen, hvor vor Life Science analytiker David Mygind denne gang kigger på den tidlige udviklingspipeline, som bygger på Genmabs teknologiplatforme Duobody og Hexabody. Til slut opsamles afsnittene i føljetonen (Darzalex, den sene pipeline og den tidlige pipeline) med en samlet værdiansættelse af Genmab. Kræver abonnement.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind